Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka, 565-0871, Japan; Laboratory of Immunochemistry, Immunology Frontier Research Center, Osaka University, 3-1 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Department of Immunology, Kanazawa Medical University, Japan.
Biochem Biophys Res Commun. 2021 Apr 9;548:167-173. doi: 10.1016/j.bbrc.2021.02.033. Epub 2021 Feb 26.
Plasmodium falciparum causes the most severe form of malaria. Acquired immunity against P. falciparum provides insufficient protection even after repeated infections. Therefore, P. falciparum parasites might exploit inhibitory receptors for immune evasion. P. falciparum RIFINs are products of a multigene family consisting of 150-200 genes. Previously, we demonstrated that some RIFINs downregulate the immune response through the leukocyte immunoglobulin-like receptor (LILR) family inhibitory receptor, LILRB1, and leukocyte-associated immunoglobulin-like receptor 1, LAIR1. In this study, we further analyzed the expression of inhibitory receptor ligands on P. falciparum-infected erythrocytes and found that P. falciparum-infected erythrocytes expressed ligands for another LILR family inhibitory receptor, LILRB2, that recognizes HLA class I molecules as a host ligand. Furthermore, we identified that a specific RIFIN was a ligand for LILRB2 by using a newly developed RIFIN expression library. In addition, the domain 3 of LILRB2 was involved in RIFIN binding, whereas the domains 1 and 2 of LILRB2 were involved in the binding to HLA class I molecules. These results suggest that inhibitory receptor LILRB2 is also targeted by RIFIN for immune evasion of P. falciparum similar to LILRB1 and LAIR1.
恶性疟原虫引起最严重的疟疾。即使在反复感染后,针对恶性疟原虫的获得性免疫也不能提供充分的保护。因此,恶性疟原虫寄生虫可能利用抑制性受体进行免疫逃避。恶性疟原虫 RIFIN 是由 150-200 个基因组成的多基因家族的产物。先前,我们证明了一些 RIFIN 通过白细胞免疫球蛋白样受体 (LILR) 家族抑制性受体 LILRB1 和白细胞相关免疫球蛋白样受体 1 (LAIR1) 下调免疫反应。在这项研究中,我们进一步分析了感染红细胞上抑制性受体配体的表达,发现恶性疟原虫感染的红细胞表达另一种 LILR 家族抑制性受体 LILRB2 的配体,该受体识别 HLA 类 I 分子作为宿主配体。此外,我们通过使用新开发的 RIFIN 表达文库鉴定出特定的 RIFIN 是 LILRB2 的配体。此外,LILRB2 的结构域 3 参与 RIFIN 结合,而 LILRB2 的结构域 1 和 2 参与与 HLA 类 I 分子的结合。这些结果表明,抑制性受体 LILRB2 也被 RIFIN 靶向,用于逃避恶性疟原虫的免疫,类似于 LILRB1 和 LAIR1。